Bank Julius Baer & Co. Ltd, Zurich Vertex Pharmaceuticals Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

$25.6 Billion
Q3 2024

A detailed history of Bank Julius Baer & Co. Ltd, Zurich transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bank Julius Baer & Co. Ltd, Zurich holds 335,645 shares of VRTX stock, worth $151 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares

335,645

Previous 13,503 2385.71%

Holding current value

$151 Million

Previous $6.33 Million 2366.44%

% of portfolio

0.61%

Previous 0.03%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $148 Million - $163 Million	322,142 Added 2385.71%	335,645 $156 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $107 Million - $132 Million	-272,605 Reduced 95.28%	13,503 $6.33 Million
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $33.6 Million - $36.8 Million	82,476 Added 40.5%	286,108 $120 Million
Q4 2023 May 16, 2024	SELL	$343.0 - $410.68 $73.5 Million - $88 Million	-214,367 Reduced 74.93%	71,741 $29.2 Million
Q4 2023 May 16, 2024	BUY	$343.0 - $410.68 $45.2 Million - $54.2 Million	131,891 Added 183.84%	203,632 $82.9 Million
Q4 2023 Feb 02, 2024	BUY	$343.0 - $410.68 $6.17 Million - $7.39 Million	18,002 Added 9.7%	203,632 $82.9 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $4.72 Million - $5.06 Million	13,969 Added 8.14%	185,630 $64.6 Million
Q2 2023 Jul 24, 2023	BUY	$314.42 - $351.91 $54 Million - $60.4 Million	171,661 New	171,661 $60.4 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $307,871 - $351,209	1,087 Added 0.64%	171,457 $54 Million
Q4 2022 Jan 24, 2023	BUY	$285.76 - $321.48 $46.4 Million - $52.2 Million	162,295 Added 2009.85%	170,370 $49.2 Million
Q3 2022 Nov 04, 2022	BUY	$273.83 - $305.53 $1.03 Million - $1.15 Million	3,767 Added 87.44%	8,075 $2.34 Million
Q2 2022 Jul 22, 2022	BUY	$234.96 - $292.55 $279,367 - $347,841	1,189 Added 38.12%	4,308 $1.21 Million
Q1 2022 May 09, 2022	BUY	$221.42 - $260.97 $588,755 - $693,919	2,659 Added 578.04%	3,119 $814,000
Q4 2021 Feb 15, 2022	SELL	$177.01 - $223.45 $799,200 - $1.01 Million	-4,515 Reduced 90.75%	460 $101,000
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $379,649 - $424,858	2,093 Added 72.62%	4,975 $902,000
Q2 2021 Jul 23, 2021	BUY	$187.49 - $221.1 $131,805 - $155,433	703 Added 32.26%	2,882 $581,000
Q1 2021 May 10, 2021	SELL	$207.02 - $241.31 $2.91 Million - $3.39 Million	-14,069 Reduced 86.59%	2,179 $468,000
Q4 2020 Feb 24, 2021	SELL	$207.01 - $276.09 $357,713 - $477,083	-1,728 Reduced 9.61%	16,248 $3.84 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $1.98 Million - $2.64 Million	9,580 Added 114.1%	17,976 $3.84 Million
Q3 2020 Nov 10, 2020	BUY	$255.65 - $303.1 $567,543 - $672,882	2,220 Added 35.95%	8,396 $2.23 Million
Q2 2020 Aug 12, 2020	SELL	$225.48 - $295.8 $191,883 - $251,725	-851 Reduced 12.11%	6,176 $1.79 Million
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $1.4 Million - $1.74 Million	7,027 New	7,027 $1.67 Million

Others Institutions Holding VRTX

# of Institutions

1,721

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

News

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.

Account

Bank Julius Baer & Co. Ltd, Zurich Vertex Pharmaceuticals Inc Transaction History